FDA updates in pediatric care: Q2 2026 recap
• On June 2, 2026, the FDA approved ensitrelvir for the post-exposure prophylaxis of COVID-19 in patients aged 12 years and older. • The regulatory decision follows positive results from phase 3 clinical trials, confirming the drug's efficacy in this demographic. • This approval provides clinicians with a critical new tool to limit the spread of the virus among adolescents following close-contact or household exposure.
contemporarypediatrics.com





